Minimum Starting Doses for Injectable GLP-1 Receptor Agonists
Start exenatide at 5 mcg twice daily, liraglutide at 0.6 mg daily, dulaglutide at 0.75 mg weekly, and semaglutide at 0.25 mg weekly. These are the FDA-approved minimum starting doses designed to minimize gastrointestinal side effects while initiating therapy 1.
Specific Starting Doses by Agent
Twice-Daily Formulations
- Exenatide (immediate-release): 5 mcg subcutaneously twice daily, administered within 60 minutes before morning and evening meals. After 1 month, increase to 10 mcg twice daily based on clinical response 1.
Once-Daily Formulations
- Liraglutide: 0.6 mg subcutaneously once daily at any time of day. After 1 week at 0.6 mg, increase to 1.2 mg daily, then to 1.8 mg daily as tolerated 1, 2.
- Lixisenatide: 10 mcg subcutaneously once daily within 60 minutes before the first meal. On day 15, increase to 20 mcg once daily 1.
Once-Weekly Formulations
- Exenatide extended-release: 2 mg subcutaneously once weekly at any time of day (no titration required) 1.
- Dulaglutide: 0.75 mg subcutaneously once weekly at any time of day. If additional glycemic control is needed, increase to 1.5 mg weekly 1, 3.
- Semaglutide (subcutaneous): 0.25 mg subcutaneously once weekly at any time of day. After 4 weeks, increase to 0.5 mg weekly. If additional control is needed, increase to 1 mg weekly after another 4 weeks at 0.5 mg 1, 4.
Oral Formulation
- Semaglutide (oral): 3 mg once daily, taken at least 30 minutes before the first food, fluid, or other oral medications with no more than 120 mL of plain water 1.
Critical Titration Principles
Slow dose escalation is mandatory to reduce nausea and vomiting, which are the most common reasons for treatment discontinuation 5, 6, 7. The delay in gastric emptying is largest after the first dose and diminishes with subsequent doses, making gradual titration essential 3.
Renal Dosing Considerations
- No dose adjustment required: Liraglutide, dulaglutide, and semaglutide can be used without dose modification across all stages of chronic kidney disease, including end-stage renal disease 1, 8.
- Use caution or avoid: Exenatide is not recommended with CrCl <30 mL/min; lixisenatide is not recommended with eGFR <15 mL/min/1.73 m² 1, 9, 8.
Common Pitfall to Avoid
Do not start at maintenance doses. Beginning therapy at higher doses (e.g., liraglutide 1.8 mg or semaglutide 0.5 mg) dramatically increases gastrointestinal adverse events and treatment discontinuation 5, 7. The starting doses listed above are specifically designed to allow GI tolerance to develop before reaching therapeutic levels.